Veröffentli­chungen
Publikationen
Wissenschaftliche Veröffentlichungen
Hier finden Sie wissenschaftliche Veröffentlichungen des BiKeR-Projektes in umgekehrt chronologischer Reihenfolge:
Incident psoriasis under treatment with tumor necrosis factor-α inhibitors in juvenile idiopathic arthritis patients-analysis of the BiKeR registry.
Zimmer A, Klein A, Kuemmerle-Deschner JB, Dressler F, Onken N, Brueck N, Fasshauer M, Hospach T, Hufnagel M, Foell D, Horneff G. Rheumatol Int. 2023 Jun 9. doi: 10.1007/s00296-023-05352-z. Online ahead of print.PMID: 37291093
Biologics with or without methotrexate in treatment of polyarticular juvenile idiopathic arthritis: effectiveness, safety and drug survival.
Thiele F, Klein A, Klotsche J, Windschall D, Dressler F, Kuemmerle-Deschner J, Minden K, Foeldvari I, Foell D, Mrusek S, Oommen PT, Horneff G.Rheumatology (Oxford). 2023 Jun 1;62(6):2230-2238. doi: 10.1093/rheumatology/keac587.PMID: 36222562
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
Broekaert IJ, Klein A, Windschall D, Rogalski B, Weller-Heinemann F, Oommen P, Küster M, Foeldvari I, Minden K, Hospach A, Hufnagel M, Berger T, Geikowski T, Quietzsch J, Horneff G.J Pediatr Gastroenterol Nutr. 2023 Feb 1;76(2):174-182. doi: 10.1097/MPG.0000000000003656. Epub 2022 Nov 18.PMID: 36399775
Oral or Parenteral Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis.
Bakry R, Klein MA, Horneff G.Eur J Rheumatol. 2022 Oct;9(4):197-205. doi: 10.5152/eurjrheum.2022.21090.PMID: 35943454
Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries.
Kearsley-Fleet L, Klotsche J, van Straalen JW, Costello W, D'Angelo G, Giancane G, Horneff G, Klein A, Láday M, Lunt M, de Roock S, Ruperto N, Schoemaker C, Vijatov-Djuric G, Vojinovic J, Vougiouka O, Wulffraat NM; UK JIA Biologics Registers Investigators Group; Paediatric Rheumatology International Trials Organisation (PRINTO); Hyrich KL, Minden K, Swart JF.Rheumatology (Oxford). 2022 May 30;61(6):2524-2534. doi: 10.1093/rheumatology/keab641.PMID: 34613385
Efficacy and Safety of Etanercept Biosimilars Compared With the Originator for Treatment of Juvenile Arthritis: A Prospective Observational Study.
Thiele F, Klein A, Hospach A, Windschall D, Mrusek S, Ruehlmann JM, Horneff G.ACR Open Rheumatol. 2021 Nov;3(11):779-787. doi: 10.1002/acr2.11325. Epub 2021 Aug 27.PMID: 34449981
Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis.
Klotsche J, Klein A, Niewerth M, Hoff P, Windschall D, Foeldvari I, Haas JP, Horneff G, Minden K.Arthritis Res Ther. 2021 Apr 16;23(1):118. doi: 10.1186/s13075-021-02492-0.PMID: 33863349
Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry.
Thiele F, Klein A, Windschall D, Hospach A, Foeldvari I, Minden K, Weller-Heinemann F, Horneff G.Rheumatol Int. 2021 Apr;41(4):751-762. doi: 10.1007/s00296-020-04774-3. Epub 2021 Feb 16.PMID: 33590331
Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry.
Raab A, Kallinich T, Huscher D, Foeldvari I, Weller-Heinemann F, Dressler F, Kuemmerle-Deschner JB, Klein A, Horneff G.Pediatr Rheumatol Online J. 2021 Mar 22;19(1):41. doi: 10.1186/s12969-021-00522-4.PMID: 33752685
Safety and efficacy of anakinra as first-line or second-line therapy for systemic onset juvenile idiopathic arthritis - data from the German BIKER registry.
Atemnkeng Ntam V, Klein A, Horneff G.Expert Opin Drug Saf. 2021 Jan;20(1):93-100. doi: 10.1080/14740338.2021.1843631. Epub 2020 Nov 18.PMID: 33148061
Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry.
Armaroli G, Klein A, Ganser G, Ruehlmann MJ, Dressler F, Hospach A, Minden K, Trauzeddel R, Foeldvari I, Kuemmerle-Deschner J, Weller-Heinemann F, Urban A, Horneff G.Arthritis Res Ther. 2020 Oct 29;22(1):258. doi: 10.1186/s13075-020-02326-5.PMID: 33121528
Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry.
Klein A, Klotsche J, Hügle B, Minden K, Hospach A, Weller-Heinemann F, Schwarz T, Dressler F, Trauzeddel R, Hufnagel M, Foeldvari I, Borte M, Kuemmerle-Deschner J, Brunner J, Oommen PT, Föll D, Tenbrock K, Urban A, Horneff G.Rheumatology (Oxford). 2020 Sep 1;59(9):2287-2298. doi: 10.1093/rheumatology/kez577.PMID: 31846042
Biologic Therapies in Polyarticular Juvenile Idiopathic Arthritis. Comparison of Long-Term Safety Data from the German BIKER Registry.
Klein A, Becker I, Minden K, Hospach A, Schwarz T, Foeldvari I, Huegle B, Borte M, Weller-Heinemann F, Dressler F, Kuemmerle-Deschner J, Oommen PT, Foell D, Trauzeddel R, Rietschel C, Horneff G.ACR Open Rheumatol. 2020 Jan;2(1):37-47. doi: 10.1002/acr2.11091. Epub 2019 Nov 24.PMID: 31943968
Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry.
Klein A, Becker I, Minden K, Foeldvari I, Haas JP, Horneff G.Scand J Rheumatol. 2019 Mar;48(2):95-104. doi: 10.1080/03009742.2018.1488182. Epub 2018 Nov 9.PMID: 30411654
Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
Swart J, Giancane G, Horneff G, Magnusson B, Hofer M, Alexeeva Е, Panaviene V, Bader-Meunier B, Anton J, Nielsen S, De Benedetti F, Kamphuis S, Staņēviča V, Tracahana M, Ailioaie LM, Tsitsami E, Klein A, Minden K, Foeldvari I, Haas JP, Klotsche J, Horne AC, Consolaro A, Bovis F, Bagnasco F, Pistorio A, Martini A, Wulffraat N, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO), BiKeR and the board of the Swedish Registry.Arthritis Res Ther. 2018 Dec 27;20(1):285. doi: 10.1186/s13075-018-1780-z.PMID: 30587248
Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA.
Klotsche J, Minden K, Niewerth M, Horneff G.Ann Rheum Dis. 2018 Jul;77(7):996-1002. doi: 10.1136/annrheumdis-2017-211968. Epub 2018 Feb 16.PMID: 29453217
Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
Horneff G, Schulz AC, Klotsche J, Hospach A, Minden K, Foeldvari I, Trauzeddel R, Ganser G, Weller-Heinemann F, Haas JP.Arthritis Res Ther. 2017 Nov 22;19(1):256. doi: 10.1186/s13075-017-1462-2.PMID: 29166924
A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities.
Beukelman T, Anink J, Berntson L, Duffy C, Ellis JA, Glerup M, Guzman J, Horneff G, Kearsley-Fleet L, Klein A, Klotsche J, Magnusson B, Minden K, Munro JE, Niewerth M, Nordal E, Ruperto N, Santos MJ, Schanberg LE, Thomson W, van Suijlekom-Smit L, Wulffraat N, Hyrich K.Pediatr Rheumatol Online J. 2017 Apr 19;15(1):31. doi: 10.1186/s12969-017-0161-5.PMID: 28424093
Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.
Horneff G, Klein A, Klotsche J, Minden K, Huppertz HI, Weller-Heinemann F, Kuemmerle-Deschner J, Haas JP, Hospach A.Arthritis Res Ther. 2016 Nov 24;18(1):272. doi: 10.1186/s13075-016-1170-3.PMID: 27881144
Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis
Windschall D, Horneff G.
Clin Rheumatol. 2016 Oct 5. [Epub ahead of print]
Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry
Horneff G, Klein A, Oommen PT, Hospach A, Foeldvari I, Feddersen I, Minden K. Clin Exp Rheumatol. 2016 Sep 8. [Epub ahead of print]
Risk of serious infection in juvenile idiopathic arthritis patients associated with TNF-inhibitors and disease activity in the German BIKER registry
Becker I, Horneff G.
Arthritis Care Res (Hoboken). 2016 Jul 7. doi: 10.1002/acr.22961. [Epub ahead of print]
Biologic-associated infections in pediatric rheumatology.
Horneff G.
Curr Rheumatol Rep. 2015 Nov;17(11):66. doi: 10.1007/s11926-015-0542-z. Review.
Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis Patients Treated with Biologics.
Barthel D, Ganser G, Kuester RM, Onken N, Minden K, Girschick HJ, Hospach A, Horneff G.
J Rheumatol. 2015 Nov;42(11):2160-5. doi: 10.3899/jrheum.140472.
Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
Foeldvari I, Becker I, Horneff G.
Arthritis Care Res (Hoboken). 2015 Nov;67(11):1529-35. doi: 10.1002/acr.22613.
Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
Klotsche J, Niewerth M, Haas JP, Huppertz HI, Zink A, Horneff G, Minden K.
Ann Rheum Dis. 2015 Apr 29. pii: annrheumdis-2014-206747. doi: 10.1136/annrheumdis-annrheumdis-2014-206747
Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 2 years.
Windschall D, Müller T, Becker I, Horneff G.
Rheumatol Int. 2015 Apr;35(4):613-8. doi: 10.1007/s00296-014-3125-9. Epub 2014 Sep 11.
Incidence of herpes zoster infections in juvenile idiopathic arthritis patients.
Nimmrich S, Horneff G.
Rheumatol Int. 2015 Mar;35(3):465-70. doi: 10.1007/s00296-014-3197-6. Epub 2015 Jan 13
[Current news from the BIKER register]
Horneff G, Minden K, Foeldvari I, Onken N, Windschall D, Hospach A, Ganser G, Klotsche J, Becker I; BIKER-Register Studiengruppe.
Z Rheumatol. 2014 Dec;73(10):897-906. doi: 10.1007/s00393-014-1397-9. German.
Predictors of response to methotrexate in juvenile idiopathic arthritis.
Albarouni M, Becker I, Horneff G.
Pediatr Rheumatol Online J. 2014 Aug 13;12:35. doi: 10.1186/1546-0096-12-35. eCollection 2014.
Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis.
Windschall D, Müller T, Becker I, Horneff G.
Clin Rheumatol. 2015 Jan;34(1):61-9. doi: 10.1007/s10067-014-2744-6. Epub 2014 Jul 18.
[Therapy of juvenile idiopathic arthritis in early adulthood with biologics: transition from pediatric to adult care]
Niewerth M, Minden K, Klotsche J, Horneff G.
Z Rheumatol. 2014 Aug;73(6):532-40. doi: 10.1007/s00393-014-1378-z. German.
Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G.
Arthritis Rheumatol. 2014 Sep;66(9):2580-9. doi: 10.1002/art.38741.
Definition of improvement in juvenile idiopathic arthritis using the juvenile arthritis disease activity score
Horneff G, Becker I.
Rheumatology (Oxford). 2014 Jul;53(7):1229-34. doi: 10.1093/rheumatology/ket470. Epub 2014 Mar 4.
Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis.
Geikowski T, Becker I, Horneff G; German BIKER Registry Collaborative Study Group.
Rheumatology (Oxford). 2014 Jul;53(7):1245-9. doi: 10.1093/rheumatology/ket490. Epub 2014 Mar 4.
Improvement in health-related quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept
Klotsche J, Minden K, Thon A, Ganser G, Urban A, Horneff G.
Arthritis Care Res (Hoboken). 2014 Feb;66(2):253-62. doi: 10.1002/acr.22112
Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry
Klein A, Kaul I, Foeldvari I, Ganser G, Urban A, Horneff G.
Arthritis Care Res (Hoboken). 2012 Sep;64(9):1349-56. doi: 10.1002/acr.21697
Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept
van Dijken TD, Vastert SJ, Gerloni VM, Pontikaki I, Linnemann K, Girschick H, Armbrust W, Minden K, Prince FH, Kokke FT, Nieuwenhuis EE, Horneff G,WulffraatNM.
J Rheumatol. 2011 Jul;38(7):1441-6. Epub 2011 Apr 1.
Report on malignancies in the German juvenile idiopathic arthritis registry
Horneff G, Foeldvari I,Minden K, Moebius D, Hospach T.
Rheumatology (Oxford). 2011 Jan;50(1):230-6.
Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis
Papsdorf V, Horneff G.
Rheumatology (Oxford). 2011 Jan;50(1):214-21. Erratum in: Rheumatology (Oxford). 2011 Apr;50(4):814
Malignancy and tumor necrosis factor inhibitors in juvenile idiopathic arthritis.
Horneff G.
Z Rheumatol. 2010 Aug;69(6):516-26. Review. German.
Updated statement by the German Society for Pediatric and Adolescent Rheumatology (GKJR) on the FDA's report regarding malignancies in anti-TNF-treated patients from Aug. 4, 2009.
Horneff G, Hospach T, Dannecker G, Föll D, Haas JP, Girschick HJ, Huppertz HI, Keitzer R, Laws HJ, Michels H, Minden K, Trauzeddel R.
Z Rheumatol. 2010 Aug;69(6):561-7. German.
Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept
Halbig M, Horneff G.
Rheumatol Int. 2009 Dec;30(2):229-38
Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry
Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H; German and Austrian Paediatric Rheumatology Collaborative Study Group.
Ann Rheum Dis. 2009 Apr;68(4):519-25. Epub 2008 Apr 15
Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years
Tzaribachev N, Kuemmerle-Deschner J, Eichner M, Horneff G.
Rheumatol Int. 2008 Aug;28(10):1031-4. Epub 2008 Mar 28
Safety and efficacy of once-weekly application of Etanercept in children with juvenile idiopathic arthritis
Kuemmerle-Deschner JB, Horneff G.
Rheumatol Int. 2007 Dec;28(2):153-6. Epub 2007 Jul 20.
Etanercept and uveitis in patients with juvenile idiopathic arthritis
Schmeling H, Horneff G.
Rheumatology (Oxford). 2005 Aug;44(8):1008-11. Epub 2005 Apr 26
Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years.
Tzaribachev N, Kuemmerle-Deschner J, Eichner M, Horneff G.
Rheumatol Int. 2008 Aug;28(10):1031-4. Epub 2008 Mar 28
Etanercept and uveitis in patients with juvenile idiopathic arthritis
Schmeling H, Horneff G.
Rheumatology (Oxford). 2005 Aug;44(8):1008-11. Epub 2005 Apr 26
The German etanercept registry for treatment of juvenile idiopathic arthritis
Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, Hospach T, Huppertz HI, Keitzer R, Küster RM, Michels H, Moebius D, Rogalski B, Thon A; Paediatric Rheumatology Collaborative Group.
Ann Rheum Dis. 2004 Dec;63(12):1638-44. Epub 2004 Apr 28. Review.